John Pieracci is the Director of the Gene Therapy Process Development department at Biogen Corporation. He is responsible for developing AAV production processes to support Biogen’s Gene Therapy portfolio. Prior to his current role, John led the downstream process development department for Biogen’s protein products. He has held a number of other management and scientific roles at Biogen and IDEC Pharmaceuticals developing, scaling up and transferring purification processes to manufacturing. He has also served as a CMC leader for multiple monoclonal antibody programs and has experience writing IND and BLA sections. John is an expert in the downstream purification and scale-up of biological products. He is the author of more than 20 scientific publications and has several patents in the area of biologics purification. John holds Master’s and Ph.D. degrees in Chemical Engineering from Rensselaer Polytechnic Institute and a Bachelor’s degree in Chemical Engineering from The University of California-Berkeley.